Morningstar | Mayne is an emerging pharmaceutical manufacturer with direct distribution into U.S. generics markets.
Through its acquisitions of Mayne Pharma International and Metrics, Mayne Pharma (formerly Halcygen) has rapidly transformed into a vertically integrated specialty drug manufacturer with proprietary drug delivery expertise and a substantial product portfolio. Mayne Pharma's stated strategy is heavily geared towards the timely introduction of enhanced generic formulations targeting niche markets, primarily in the U.S., which has been significantly expanded with the recent generic portfolio acquisition. In the medium term, the company aims to win significant market share that is less vulnerable to price erosion. Mayne's vertical integration strategy promises synergy gains through cross-selling opportunities across multiple geographies. Uncertainty in the timing of new product approvals provides impetus for ongoing brand acquisitions in order to build scale and increases the risk of dilution to existing shareholders.Mayne Pharma is a pharmaceutical company focused on applying its drug delivery capabilities to commercialize branded and generic pharmaceuticals. Co. operates in four business units: Generic Products, which develops, manufactures, markets and distributes generic pharmaceutical products in the U.S.; Specialty Brands, which markets and distributes specialty branded pharmaceutical products in the U.S.; Metrics Contract Services, which provides contract pharmaceuticals development services and analytical services to third parties; and Mayne Pharma International, which develops, manufactures, markets and distributes branded and generic pharmaceutical products globally, excluding the U.S.
Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.
Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.
We have operations in 27 countries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.